Intarcia Therapeutics IPO

Intarcia is a biotech company dedicated to redesigning the treatment, prevention and experience of chronic disease.

Register for Details

For more details on financing and valuation for Intarcia Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Who are Intarcia Therapeutics's major investors?

New Enterprise Associates
GGV Capital
Foresite Capital
Farallon Capital Management
Fred Alger Management
New Leaf Venture Partners
RA Capital

Intarcia Therapeutics Funding Rounds and IPO Valuation

Date Funding Round Funding Raised Price per Share IPO Valuation
9/15/2016 Series EE $475.68MM raised $XXX.XX $XXX.XX
7/4/2014 Series DD $200MM raised $XXX.XX $XXX.XX
11/15/2012 Series CC $210MM raised $XXX.XX $XXX.XX
1/14/2010 Series BB-3 $7.87MM raised $XXX.XX $XXX.XX
4/28/2008 Series BB-2 $24.99MM raised $XXX.XX $XXX.XX
3/9/2007 Series BB-1 $23.84MM raised $XXX.XX $XXX.XX
12/1/2004 Series AA $19.08MM raised $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data

Learn more about Intarcia Therapeutics

Forge green plus iconForge green minus icon

What is Intarcia Therapeutics funding to date?

Intarcia Therapeutics has raised $961.46MM to date.
Forge green plus iconForge green minus icon

When was Intarcia Therapeutics founded?

Intarcia Therapeutics was founded in 1995.
Updated on: Jun 12, 2022